Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience

BACKGROUND/AIM: Gemcitabine, dexamethasone and cisplatin (GDP) is a well-established salvage regimen for relapsed and refractory lymphomas. In this study, we aimed to share our experience with the patients who received GDP/R-GDP (rituximab-gemcitabine, dexamethasone and cisplatin) for stem cell mobi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Turk J Med Sci
Main Authors: BATGİ, Hikmettullah, BAŞCI1, Semih, DAL1, Mehmet Sinan, KIZIL ÇAKAR, Merih, UNCU ULU, Bahar, YİĞENOĞLU, Tuğçe Nur, ÖZCAN, Nurgül, KILINÇ, Ali, MERDİN, Alparslan, YILDIZ, Jale, BAKIRTAŞ, Mehmet, ŞAHİN, Derya, DARÇIN, Tahir, İSKENDER, Dicle, BAYSAL, Nuran Ahu, ALTUNTAŞ, Fevzi
Formato: Artigo
Idioma:Inglês
Publicado em: The Scientific and Technological Research Council of Turkey 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8203130/
https://ncbi.nlm.nih.gov/pubmed/33237657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3906/sag-2008-114
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados